Published in Ger Med Sci on February 13, 2006
Trial Watch: Peptide vaccines in cancer therapy. Oncoimmunology (2013) 1.04
Therapeutic vaccines in renal cell carcinoma. Therapy (2011) 0.77
Reporting results of cancer treatment. Cancer (1981) 28.83
Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med (2000) 4.99
Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods (1999) 3.09
The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity (1999) 2.06
Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol (2000) 1.44
A new antigen recognized by cytolytic T lymphocytes on a human kidney tumor results from reverse strand transcription. J Exp Med (1999) 1.08
Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes. Blood (2001) 1.05
Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Hum Gene Ther (2003) 1.04
Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. Clin Cancer Res (2001) 1.02
Efficient priming of antigen-specific cytotoxic T lymphocytes by human cord blood dendritic cells. Int Immunol (2003) 0.96
Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience. J Clin Oncol (1999) 0.94
Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial. Cancer Immunol Immunother (2002) 0.91
Rapid deterioration in quality of life during interleukin-2- and alpha-interferon-based home therapy of renal cell carcinoma is associated with a good outcome. Br J Cancer (2003) 0.90
In vitro induction of carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenoviruses. Vaccine (2003) 0.90
Immune response induced in vitro by CD16- and CD16+ monocyte-derived dendritic cells in patients with metastatic renal cell carcinoma treated with dendritic cell vaccines. J Clin Immunol (2004) 0.88
Telomerase pulsed dendritic cells for immunotherapy for renal cell carcinoma. J Urol (2004) 0.85
[Tumor vaccination in renal cell carcinoma with and without interleukin-2 (IL-2) as adjuvant. A clinical contribution to the development of effective active specific immunization]. Urologe A (1995) 0.80
Low antigen-dependent activity of T cells after repeated stimulation using dendritic cells and expansion with interleukin-2. Neoplasma (2003) 0.79
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med (2007) 24.19
Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet (2003) 4.88
Three-dimensional maps of all chromosomes in human male fibroblast nuclei and prometaphase rosettes. PLoS Biol (2005) 4.33
Frequency of the HIV-protective CC chemokine receptor 5-Delta32/Delta32 genotype is increased in hepatitis C. Gastroenterology (2002) 3.96
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol (2012) 3.93
Chromosome territories--a functional nuclear landscape. Curr Opin Cell Biol (2006) 3.82
Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity. Proc Natl Acad Sci U S A (2002) 2.85
HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. Proc Natl Acad Sci U S A (2003) 2.73
Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology (2010) 2.60
The SUMO E3 ligase RanBP2 promotes modification of the HDAC4 deacetylase. EMBO J (2002) 2.56
Evolutionary conservation of chromosome territory arrangements in cell nuclei from higher primates. Proc Natl Acad Sci U S A (2002) 2.53
Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy. Science (2008) 2.51
Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology (2004) 2.45
Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol (2011) 2.45
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood (2011) 2.37
Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983. J Clin Oncol (2012) 2.36
Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection. Eur Urol (2008) 2.34
Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes (2011) 2.29
Interferon-lambda serum levels in hepatitis C. J Hepatol (2010) 2.28
Strategy for safe performance of extrathoracic magnetic resonance imaging at 1.5 tesla in the presence of cardiac pacemakers in non-pacemaker-dependent patients: a prospective study with 115 examinations. Circulation (2006) 2.25
Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. Hum Mol Genet (2006) 2.23
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol (2007) 2.21
p-ANCAs in autoimmune liver disorders recognise human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ. Gut (2009) 2.20
Atypical Ormond's disease associated with bile duct stricture mimicking cholangiocarcinoma. Scand J Gastroenterol (2009) 2.17
Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol (2003) 2.14
RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. J Clin Oncol (2011) 2.11
Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology (2013) 2.08
Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05). Eur Urol (2008) 2.02
Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology (2007) 1.95
Strumpellin is a novel valosin-containing protein binding partner linking hereditary spastic paraplegia to protein aggregation diseases. Brain (2010) 1.93
Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). J Clin Oncol (2005) 1.93
Cellular targets of gefitinib. Cancer Res (2005) 1.87
MDRD equations for estimation of GFR in renal transplant recipients. Am J Transplant (2005) 1.82
Active surveillance is the preferred approach to clinical stage I testicular cancer. J Clin Oncol (2013) 1.81
Treatment of penile strangulation caused by constricting devices. Urology (2002) 1.81
MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS One (2011) 1.79
Neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: which patients benefit? Eur Urol (2013) 1.75
The Arabidopsis elch mutant reveals functions of an ESCRT component in cytokinesis. Development (2006) 1.74
Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology (2011) 1.73
Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol (2003) 1.71
beta-Trace protein is an alternative marker for glomerular filtration rate in renal transplantation patients. Clin Chem (2005) 1.71
The International Testicular Cancer Linkage Consortium: a clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred. Urol Oncol (2009) 1.70
Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme. Eur Urol (2012) 1.69
Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol (2006) 1.68
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol (2012) 1.64
Predictors of occult metastasis in clinical stage I nonseminoma: a systematic review. J Clin Oncol (2003) 1.63
DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis. Leuk Lymphoma (2006) 1.61
The SBML ODE Solver Library: a native API for symbolic and fast numerical analysis of reaction networks. Bioinformatics (2006) 1.61
Inducible nitric oxide synthase (iNOS) and endothelial nitric oxide synthase (eNOS) expression in fulminant hepatic failure. J Hepatol (2002) 1.60
Natural killer p46High expression defines a natural killer cell subset that is potentially involved in control of hepatitis C virus replication and modulation of liver fibrosis. Hepatology (2012) 1.60
Pseudomembranous and obstructive Aspergillus tracheobronchitis - optimal diagnostic strategy and outcome. Mycoses (2006) 1.58
Automated low flow pump system for the treatment of refractory ascites: a multi-center safety and efficacy study. J Hepatol (2013) 1.57
Characterization of peptides released from mitochondria: evidence for constant proteolysis and peptide efflux. J Biol Chem (2004) 1.53
Multicolor 3D fluorescence in situ hybridization for imaging interphase chromosomes. Methods Mol Biol (2008) 1.52
Comparative study of NK cell-mediated cytotoxicity using radioactive and flow cytometric cytotoxicity assays. J Immunol Methods (2005) 1.51
The HLA-A2 restricted T cell epitope HCV core 35-44 stabilizes HLA-E expression and inhibits cytolysis mediated by natural killer cells. Am J Pathol (2005) 1.48
Bleeding complications after percutaneous liver biopsy. An analysis of risk factors. Digestion (2003) 1.48
False positive 18F-FDG-PET/CT in a patient after talc pleurodesis. Lung Cancer (2007) 1.47
Regulation of CC chemokine receptor 5 in hepatitis G virus infection. AIDS (2003) 1.47
Treatment of bile duct-ligated rats with the nitric oxide synthase transcription enhancer AVE 9488 ameliorates portal hypertension. Liver Int (2008) 1.46
Comparison of MELD, Child-Pugh, and Emory model for the prediction of survival in patients undergoing transjugular intrahepatic portosystemic shunting. Am J Gastroenterol (2003) 1.46
Pitfalls in the diagnosis of intestinal tuberculosis: a case report. Scand J Gastroenterol (2005) 1.46
Ultrasound confirmation of central venous catheter position via a right supraclavicular fossa view using a microconvex probe: an observational pilot study. Eur J Anaesthesiol (2015) 1.45
Organ-sparing surgery for adult testicular tumours: a systematic review of the literature. Eur Urol (2010) 1.43
Subinhibitory concentrations of linezolid reduce Staphylococcus aureus virulence factor expression. Antimicrob Agents Chemother (2004) 1.43
Neutropenic enterocolitis in adults: systematic analysis of evidence quality. Eur J Haematol (2005) 1.42
Implantation of artificial penile nodules--a review of literature. J Sex Med (2010) 1.41
Histopathological and molecular features of late relapses in non-seminomas. BJU Int (2010) 1.40
Circulating microRNAs in serum: novel biomarkers for patients with bladder cancer? World J Urol (2012) 1.39
Are molecular cytogenetics and bioinformatics suggesting diverging models of ancestral mammalian genomes? Genome Res (2006) 1.38
Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol (2010) 1.38
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol (2007) 1.37
Coronary MR angiography at 3.0 T versus that at 1.5 T: initial results in patients suspected of having coronary artery disease. Radiology (2005) 1.35
Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. J Hepatol (2012) 1.34
Structural characterization of TSC-36/Flik: analysis of two charge isoforms. J Biol Chem (2003) 1.33
Late relapse of testicular germ cell neoplasms: a descriptive analysis of 122 cases. J Urol (2005) 1.32
Synergy of glucose and growth hormone signalling in islet cells through ICA512 and STAT5. Nat Cell Biol (2006) 1.31
Chemical proteomic analysis reveals alternative modes of action for pyrido[2,3-d]pyrimidine kinase inhibitors. Mol Cell Proteomics (2004) 1.28
Genotyping NAT2 with only two SNPs (rs1041983 and rs1801280) outperforms the tagging SNP rs1495741 and is equivalent to the conventional 7-SNP NAT2 genotype. Pharmacogenet Genomics (2011) 1.27
Flow-structure-acoustic interaction in a human voice model. J Acoust Soc Am (2009) 1.27
Acquisition protocol considerations for combined PET/CT imaging. J Nucl Med (2004) 1.27
Interaction of G alpha(12) with G alpha(13) and G alpha(q) signaling pathways. Proc Natl Acad Sci U S A (2002) 1.27
Phase II study of photodynamic therapy and metal stent as palliative treatment for nonresectable hilar cholangiocarcinoma. Gastrointest Endosc (2003) 1.27
Intestinal oxalate absorption is higher in idiopathic calcium oxalate stone formers than in healthy controls: measurements with the [(13)C2]oxalate absorption test. J Urol (2006) 1.26
Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term followup. J Urol (2007) 1.26
CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology (2008) 1.24
Oxidative damage is increased in human liver tissue adjacent to hepatocellular carcinoma. Hepatology (2004) 1.24
Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. J Hepatol (2012) 1.23
Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. J Clin Oncol (2007) 1.22
Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin Cancer Res (2005) 1.22
Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling. Cancer Res (2005) 1.21
Induction of Bim and Bid gene expression during accelerated apoptosis in severe sepsis. Crit Care (2008) 1.21
Viral oncoproteins E1A and E7 and cellular LxCxE proteins repress SUMO modification of the retinoblastoma tumor suppressor. Oncogene (2005) 1.21
Nucleotide-binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis. Hepatology (2010) 1.20
Analysis of serum microRNAs (miR-26a-2*, miR-191, miR-337-3p and miR-378) as potential biomarkers in renal cell carcinoma. Cancer Epidemiol (2012) 1.20
Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol (2003) 1.19